Department of Nephrology and Dialysis, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
Nephrol Dial Transplant. 2013 May;28(5):1232-40. doi: 10.1093/ndt/gfs548. Epub 2013 Jan 4.
Calciphylaxis is a life-threatening complication in patients with end-stage renal disease (ESRD). No established therapy exists so far. The aim of the present study was to determine the therapeutic response to a multi-interventional treatment regimen with consistent use of sodium thiosulphate (STS) in an Austrian cohort of calciphylaxis patients.
We retrospectively collected demographic, clinical and laboratory data on 27 calciphylaxis patients treated with STS at seven Austrian dialysis centres between June 2004 and November 2010.
Twenty-seven dialysis patients (68 ± 12 years) were treated with STS for a median (25th, 75th percentile) of 96 (54, 133) days. Seven patients (26%) suffered from proximal-type, and 20 patients (74%) from distal-type calciphylaxis. Fourteen patients (52%) showed a complete remission, five patients (19%) a partial remission and eight patients (30%) progression that resulted in amputation in four patients. During a median follow-up of 101 (79, 273) days, 14 patients died (52%). Non-survivors were older (P = 0.04), showed higher CRP values (P = 0.04), presented more frequently with proximal-type calciphylaxis (P = 0.03), had a higher disease severity score at diagnosis (P = 0.01), were treated more often with antibiotics (P = 0.01) and cinacalcet (P = 0.03) and had a lower remission rate during treatment (P = 0.004) than did survivors. The use of antibiotics and cinacalcet, disease severity at diagnosis and remission rates were found to be significant survival predictors in logistic regression analysis.
Calciphylaxis remains a serious complication with high mortality. Early and consistent therapy including STS may help to improve the disease outcome.
钙化防御是终末期肾病(ESRD)患者的一种危及生命的并发症。目前尚无既定的治疗方法。本研究的目的是确定在奥地利钙化防御患者队列中使用硫代硫酸钠(STS)的多介入治疗方案的治疗反应。
我们回顾性地收集了 2004 年 6 月至 2010 年 11 月在奥地利七个透析中心接受 STS 治疗的 27 例钙化防御患者的人口统计学、临床和实验室数据。
27 例透析患者(68±12 岁)接受 STS 治疗,中位数(25%,75%分位数)为 96(54,133)天。7 例(26%)患者患有近端型,20 例(74%)患者患有远端型钙化防御。14 例(52%)患者完全缓解,5 例(19%)患者部分缓解,8 例(30%)患者进展导致 4 例患者截肢。在中位数为 101(79,273)天的随访期间,14 例患者死亡(52%)。非幸存者年龄较大(P=0.04),C 反应蛋白(CRP)值较高(P=0.04),更常出现近端型钙化防御(P=0.03),诊断时疾病严重程度评分较高(P=0.01),更常接受抗生素(P=0.01)和西那卡塞(P=0.03)治疗,治疗期间缓解率较低(P=0.004)。在逻辑回归分析中,抗生素和西那卡塞的使用、诊断时的疾病严重程度和缓解率被发现是显著的生存预测因素。
钙化防御仍然是一种严重的并发症,死亡率很高。早期和一致的治疗,包括 STS,可能有助于改善疾病结局。